scholarly journals The Antibacterial Activity of Amber Honey and White Honey on Pseudomonas aeruginosa Multi Resistant (PaMR) and Methicillin Resistant Staphylococcus aureus (MRSA)

2020 ◽  
Vol 11 (2) ◽  
pp. 74
Author(s):  
Faisal Yusuf Ashari ◽  
Setio Harsono ◽  
Manik Retno Wahyunitisari
Keyword(s):  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Antibacterial Activity ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Inhibitory Concentration ◽  
Modern Medicine ◽  
Test Phase ◽  
Burn Wound ◽  
Methicillin Resistant ◽  
Natural Substance

Introduction: Infection of burn wound is a chronical disturbance to the skin, which is caused by Staphylococcus aureus and Pseudomonas aeruginosa, but lately many cases found that both bacteria have been resistant to the antibiotic. To overcome the infection caused by those bacteria, it is important to search for natural substance that has antibacterial activity to both bacteria. The power of natural substance is underestimated. Studies reveal that honey can be more effective for healing burns than modern medicine. The previous research revealed that amber honey and white honey were used as an alternative treatment against Pseudomonas aeruginosa Multi Resistant (PaMR) and Methicillin Resistant Staphylococcus aureus (MRSA). The aim of this study was to evaluate the antibacterial activity of amber honey and white honey on PaMR and MRSA.Methods: This research was conducted by performing antibacterial test phase, determining Minimum Inhibitory Concentration (MIC), and determining comparison value of antibacterial activity from amber honey and white honey to tetracycline.Results: The result of this research showed that both amber honey and white honey have antibacterial activity to both bacteria, by way of stronger antibacterial activity from white honey than amber honey. Amber honey and white honey have the same PaMR activity. MIC of white honey was 7.1% (to MRSA) and 12.3% (to PaMR), while MIC of amber honey was 10% (to MRSA) and 12.5% (to PaMR). The comparison value of antibacterial activity between amber honey and white honey to tetracycline for MRSA was equal to 1:1.08 x 10-4 and 1:1.62 x 10-4. The comparison value of antibacterial activity between amber honey and white honey to tetracycline for PaMR was equal to 1:5.62 x 10-6 and 1:1.03 x 10-5 .Conclusion: Amber honey and white honey have antibacterial activity against MRSA and PaMR. 

scholarly journals Antibacterial Activity and Acute Toxicity Testing of Biosynthesized Silver Nanoparticles against Methicilin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa

2021 ◽  
Author(s):  
Ifeyomi Wilfred Olobayotan ◽  
Bukola Catherine Akin-Osanaiye ◽  
Olukemi A. Onuh
Keyword(s):  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Silver Nanoparticles ◽  
Antibacterial Activity ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Toxicity Testing ◽  
Therapeutic Agents ◽  
Methicillin Resistant ◽  
Colony Forming Units ◽  
Test Organisms

Antibacterial activity of biosynthesized silver nanoparticles was studied using the macrobroth dilution technique. The silver nanoparticles was significantly active (p > 0.05) against the test organisms at an extract concentration of 75 µg/ml. Concentrations ≤ 50 µg/ml were not as effective as the colony forming units at this concentration, 1.61 x 106 for methicillin-resistant Staphylococcus aureus and concentrations ≤ 25 µg/ml 1.45 x 106 for Pseudomonas aeruginosa respectively, were about the same range as the colony forming units of the controls. The silver nanoparticles inhibited Methicillin-Resistant S. aureus more (MIC of 75 µg/ml and MBC of 100 µg/ml) than they inhibited P. aeruginosa (both MIC and MBC was 100 µg/ml). The LD50 of the synthesized silver nanoparticles after oral administration was seen to be greater than 5000 mg/kg body weight and is therefore thought to be safe. This study supports the use of silver nanoparticles as therapeutic agents. KEYWORDS: Nanoparticles, Biosynthesis, Inhibition, Therapeutic agents, Macroboth Technique

scholarly journals In Vivo Antibacterial Activity of S-3578, a New Broad-Spectrum Cephalosporin: Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Experimental Infection Models

2003 ◽  
Vol 47 (8) ◽  
pp. 2507-2512 ◽  
Author(s):  
Masakatsu Tsuji ◽  
Morio Takema ◽  
Hideaki Miwa ◽  
Jingoro Shimada ◽  
Shogo Kuwahara
Keyword(s):  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Antibacterial Activity ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Pulmonary Infections ◽  
Methicillin Resistant ◽  
Infection Models ◽  
Systemic Infections

ABSTRACT The in vivo antibacterial activity of S-3578, a new parental cephalosporin, was compared with those of cefepime, ceftriaxone, ceftazidime, imipenem-cilastatin, and vancomycin. The efficacy of S-3578 against systemic infections caused by methicillin-resistant Staphylococcus aureus (MRSA) SR3637 (50% effective dose [ED50], 7.21 mg/kg of body weight) was almost the same as that of vancomycin. In contrast, cefepime and imipenem-cilastatin were less active against this pathogen (ED50s, >100 and >100 mg/kg, respectively). S-3578 was the most effective compound against penicillin-resistant Streptococcus pneumoniae SR20946 (ED50, 1.98 mg/kg). S-3578 (10 mg/kg) induced a significant reduction in the numbers of viable MRSA SR17764 and Pseudomonas aeruginosa SR10396 organisms in polymicrobial pulmonary infections. The therapeutic efficacy of S-3578 was more potent than that of the combination of vancomycin and ceftazidime. High levels of S-3578 were detected in plasma in vivo, and its efficacy against experimentally induced infections in mice caused by MRSA and P. aeruginosa reflected its potent in vitro activity. We conclude that S-3578 is a promising new cephalosporin for the treatment of infections caused by gram-positive and -negative bacteria, including MRSA and P. aeruginosa.

scholarly journals THE ANTIBIOFILM ACTIVITY OF HIBISCUS SABDRIFFA L. AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

2021 ◽  
Vol 52 (3) ◽  
pp. 626-631
Author(s):  
Jaddoa & Gharb
Keyword(s):  
Staphylococcus Aureus ◽  
Antibacterial Activity ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Inhibitory Concentration ◽  
Ethanolic Extract ◽  
Diffusion Method ◽  
Antibiofilm Activity ◽  
Dependent Manner ◽  
Hibiscus Sabdariffa ◽  
Methicillin Resistant

The current study was aimed to investigate the antibacterial and antibiofilm activity of ethanolic extract of Hibiscus sabdariffa L. calyx against locally isolated methicillin-resistant Staphylococcus aureus (MRSA) at different concentrations were started from 0.078 to 40 mg/ml. The extract was prepared by soaked calyces powder of Hibiscus sabdariffa L. with 80% ethanol in the Soxhlet extraction unit, and then it was aseptically filtered. The antibacterial activity was tested by agar diffusion method and broth microdilution method, this method was used to determine the minimum inhibitory concentration of extract, while the antibiofilm activity was determined by using 96-well polystyrene microtiter plates. The results revealed that the ethanolic extract has antibacterial activity in a concentration-dependent manner, the average diameter zone of inhibition observed against MRSA isolates ranged from 14±0.5 mm to 20±0.5 mm Moreover, at sub-inhibitory concentration, this extract developed an isolate-specific antibiofilm effect and presented highly significant (P< 0.05) variability in biofilm formation before and after addition of ethanolic extract, Mr1, and Mr7 isolates were gave the lowest and highest antibiofilm activity, respectively. In conclusion, the ethanolic extract of H. sabdariffa L. calyx is a promising alternative medication that can be used to treat the infection caused by MRS.

scholarly journals Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa

2008 ◽  
Vol 52 (8) ◽  
pp. 2849-2854 ◽  
Author(s):  
Tetsufumi Koga ◽  
Nobuhisa Masuda ◽  
Masayo Kakuta ◽  
Eiko Namba ◽  
Chika Sugihara ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Antibacterial Activity ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Clinical Isolates ◽  
Penicillin Binding Protein ◽  
Multidrug Efflux ◽  
Methicillin Resistant ◽  
Multidrug Efflux Pumps

ABSTRACT Tomopenem (formerly CS-023) is a novel 1β-methylcarbapenem with broad-spectrum coverage of gram-positive and gram-negative pathogens. Its antibacterial activity against European clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa was compared with those of imipenem and meropenem. The MICs of tomopenem against MRSA and P. aeruginosa at which 90% of the isolates tested were inhibited were 8 and 4 μg/ml, respectively, and were equal to or more than fourfold lower than those of imipenem and meropenem. The antibacterial activity of tomopenem against MRSA was correlated with a higher affinity for the penicillin-binding protein (PBP) 2a. Its activity against laboratory mutants of P. aeruginosa with (i) overproduction of chromosomally coded AmpC β-lactamase; (ii) overproduction of the multidrug efflux pumps MexAB-OprM, MexCD-OprJ, and MexEF-OprN; (iii) deficiency in OprD; and (iv) various combinations of AmpC overproduction, MexAB-OprM overproduction, and OprD deficiency were tested. The increases in the MIC of tomopenem against each single mutant compared with that against its parent strain were within a fourfold range. Tomopenem exhibited antibacterial activity against all mutants, with an observed MIC range of 0.5 to 8 μg/ml. These results suggest that the antibacterial activity of tomopenem against the clinical isolates of MRSA and P. aeruginosa should be ascribed to its high affinity for PBP 2a and its activity against the mutants of P. aeruginosa, respectively.

Sign in / Sign up

Export Citation Format

Share Document